Clinical trials: Imatinib Therapy Response
Leukemia, Myeloid, Chronic-Phase (CML-CP)
Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey
The purpose of this study is to determine predictive value of Hammersmith score on Complete Cytogenetic Response (CCyR).
- Trial name
- NCT01188278
- Testing
- Imatinib
- Volunteers
- 173 people
- Sponsor
- Bristol-Myers Squibb
Chronic Myeloid Leukemia
Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha
To investigate whether patients with chronic-phase chronic myeloid leukemia (CP-CML) previously treated with interferon-alpha (IFN) and presently on a tyrosine kinase inhibitor (TKI) (imatinib mesylate, dasatinib, or nilotinib)…
- Trial name
- NCT01073436
- Testing
- Discontinuation of therapy
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan Rogel Cancer Center
Chronic Myeloid Leukaemia
De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia
The purpose of this study is to investigate whether some patients with excellent responses to chronic myeloid leukaemia (CML) treatment are being overtreated, and can remain well on either a lower dose of treatment or without…
- Trial name
- DESTINY (NCT01804985)
- Testing
- Imatinib, nilotinib, dasatinib
- Where
- United Kingdom
- Volunteers
- 174 people
- Sponsor
- University of Liverpool
Imatinib Therapy Response, Gastrointestinal Stromal Tumor (GIST)
Hyperpolarized MRI for GIST on Imatinib
Conventional imaging methods, such as CT and MRI, are limited in evaluating GIST response to imatinib, as they mainly reflect tumor size and fail to capture early metabolic or molecular changes.
- Trial name
- DNP_GIST (NCT07724626)
- Testing
- Hyperpolarized 13C-MRI
- Where
- Taiwan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
COVID-19
The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia
A randomized controlled pilot study on the safety \& efficacy of imatinib for the treatment of patient with moderate to severe SARS-COV-2 induced pneumonia.
- Trial name
- NCT04422678
- Testing
- Imatinib Mesylate, Standard of Care
- Volunteers
- 30 people
- Sponsor
- Alexandria University
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)
Chronic myeloid leukemia (CML) is a hematopoietic neoplasm characterized by the reciprocal translocation t(9;22). The resulting oncoprotein, bcr-abl is an essential trigger for growth and survival of leukemic cells.
- Trial name
- NiloPost-STIM (NCT01774630)
- Testing
- Nilotinib
- Where
- 10 sites in France
- Volunteers
- 31 people
- Sponsor
- University Hospital, Bordeaux
Chronic Myelogenous Leukemia (CML)
Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation
This study on patient's compliance in clinical workaday life aims to assess and to improve CML treatment in Germany by means of adherence supporting measures and to increase adherence awareness by physicians and patients.
- Trial name
- Crescendo (NCT01243489)
- Testing
- compliance supporting measures
- Where
- 23 sites in Germany
- Volunteers
- 104 people
- Sponsor
- Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Leukemia, Myeloid, Philadelphia-Positive
Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy
The study is controlled and randomized in Philadelphia-positive chronic myeloid leukemia (Ph+ CML) patients with complete cytogenetic response after more than one year of imatinib therapy.
- Trial name
- NCT00297570
- Testing
- Pegylated Interferon and Imatinib
- Where
- Israel
- Volunteers
- 90 people
- Sponsor
- Sheba Medical Center
Myeloid Leukemia, Chronic
Registration of Children With CML and Treatment With Imatinib
Newly diagnosed pediatric patients (age < 19 years) with bcr-abl-positive CML will be treated with imatinib. Serial monitoring of treatment response is performed in one month intervals during the first three months of treatment…
- Trial name
- CML-paed II (NCT00445822)
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Technische Universität Dresden
Leukemia
A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy
The purpose of this clinical research study is to compare the rate of complete cytogenetic response of dasatinib to imatinib therapy at 6 months after randomization in chronic phase CML patients.
- Trial name
- NCT00362466
- Testing
- Dasatinib, Imatinib
- Where
- 45 sites in United States
- Volunteers
- 3 people
- Sponsor
- Bristol-Myers Squibb
Leukemia, Chronic Myeloid
Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response
The purpose of this study is to evaluate treatment-free remission after imatinib discontinuation in patients with chronic myeloid leukemia with deep molecular response.
- Trial name
- EDI-PIO (NCT02852486)
- Testing
- Pioglitazone 30 Mg Oral Tablet, imatinib discontinuation
- Where
- Brazil
- Volunteers
- 31 people
- Sponsor
- University of Campinas, Brazil
Leukemia, Myeloid, Chronic-Phase
Pioglityazone and Imatinib for CML Patients
This project is a Phase II clinical trial that aims at evaluating efficacy and tolerance of the combination of pioglitazone (Actos®) and imatinib mesylate (STI571, CGP57148, Gleevec®) in patients with Chronic Myelogenous Leukemia…
- Trial name
- ACTIM (NCT02888964)
- Testing
- Add-on therapy
- Where
- 9 sites in France
- Volunteers
- 27 people
- Sponsor
- Versailles Hospital
Leukemia, Other, Cancer
A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec
1.0 OBJECTIVES 1.1 To test the activity of arsenic trioxide in combination with imatinib in patients with CML with cytogenetic evidence of residual disease. 1.2 To determine the toxicity associated with this therapy.
- Trial name
- NCT00250042
- Testing
- Gleevec and Arsenic Trioxide
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- New Mexico Cancer Research Alliance
Chronic Myelogenous Leukemia
Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia
The results of the International Randomized Study of Interferon and STI571 (IRIS) trial indicate that in patients with chronic phase CML treated with first line imatinib, achievement of a complete or partial cytogenetic response…
- Trial name
- NCT01316250
- Testing
- Nilotinib
- Where
- Lebanon
- Volunteers
- 13 people
- Sponsor
- American University of Beirut Medical Center
Chronic Phase Chronic Myeloid Leukemia
Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response
In this phase I pilot study, it is planned to investigate the feasibility and safety of adding an interferon therapy to an preexisting imatinib treatment in patients with chronic phase chronic myeloid leukaemia.
- Trial name
- NCT01933906
- Testing
- P1101
- Where
- 4 sites in Austria
- Volunteers
- 12 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Chronic Myeloid Leukemia
Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
Trial try to assess the efficacy of dasatinib in terms of major molecular response rate at 6 months in patients with CP-CML who have achieved complete cytogenetic response without major molecular response after at least 18 months…
- Trial name
- DASAPOST (NCT01802450)
- Testing
- Dasatinib
- Where
- 15 sites in Spain
- Volunteers
- 18 people
- Sponsor
- PETHEMA Foundation
Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST)
A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments
This trial is a prospective, randomized (1:1 ratio), multicenter, comparative and phase II study, conducted in patients with unresectable advanced gastrointestinal stromal tumors (GIST) after failure of imatinib (disease…
- Conditions
- Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST), Metastatic Gastrointestinal Stromal Tumor
- Trial name
- ATEZOGIST (NCT05152472)
- Testing
- Atezolizumab 1200 mg, Imatinib 400 MG
- Where
- 13 sites in France
- Volunteers
- 58 people
- Sponsor
- Centre Leon Berard
Chronic Myeloid Leukemia
Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia (CML) Patients With Complete Cytogenetic Response After Imatinib as First Line Therapy
Rationale: At present, virtually no evidence exists regarding mid to long-term patient-reported health outcomes (e.g., health related quality of life-HRQOL) of CML patients treated with Imatinib.
- Trial name
- NCT00896129
- Testing
- HRQOL Survey Packet
- Where
- 25 sites in Italy
- Volunteers
- 448 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Philadelphia Positive (Ph+) Chronic Myeloid Leukemia
Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib
Primary Objective for this study is to evaluate changes in chronic low grade non-hematological adverse events experienced by patients who have been treated with at least 6 months of imatinib and who have not responded to…
- Trial name
- MACS1532 (NCT02115386)
- Testing
- Nilotinib
- Where
- Russia
- Volunteers
- 7 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia
Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill cancer cells. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or…
- Trial name
- CML0206 (NCT00466726)
- Testing
- bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine, sargramostim
- Where
- 17 sites in Italy
- Volunteers
- 57 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto